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ABSTRACT
Background The molecular genetic basis of pulmonary 
arterial hypertension (PAH) is heterogeneous, with at 
least 26 genes displaying putative evidence for disease 
causality. Heterozygous variants in the ATP13A3 gene 
were recently identified as a new cause of adult- onset 
PAH. However, the contribution of ATP13A3 risk alleles 
to child- onset PAH remains largely unexplored.
Methods and results We report three families with 
a novel, autosomal recessive form of childhood- onset 
PAH due to biallelic ATP13A3 variants. Disease onset 
ranged from birth to 2.5 years and was characterised 
by high mortality. Using genome sequencing of parent–
offspring trios, we identified a homozygous missense 
variant in one case, which was subsequently confirmed 
to cosegregate with disease in an affected sibling. 
Independently, compound heterozygous variants in 
ATP13A3 were identified in two affected siblings and in 
an unrelated third family. The variants included three loss 
of function variants (two frameshift, one nonsense) and 
two highly conserved missense substitutions located in 
the catalytic phosphorylation domain. The children were 
largely refractory to treatment and four died in early 
childhood. All parents were heterozygous for the variants 
and asymptomatic.
Conclusion Our findings support biallelic predicted 
deleterious ATP13A3 variants in autosomal recessive, 
childhood- onset PAH, indicating likely semidominant 
dose- dependent inheritance for this gene.
BACKGROUND
Pulmonary arterial hypertension (PAH (MIM: 
178 600)) is a disease of complex aetiology, clini-
cally characterised by incomplete penetrance, sex 
bias and variable age of onset, both within and 
between families. While most families exhibit 
autosomal dominant transmission, rare exam-
ples of autosomal recessive inheritance have been 
observed.1 2 The major genetic risk factor for both 
familial (ie, heritable PAH (HPAH)) and idiopathic 
PAH (IPAH) is haploinsufficiency of the bone 
morphogenetic protein receptor 2 gene (BMPR2).1 2 
However, approximately 80% of IPAH cases remain 
genetically undiagnosed. Recent sequencing studies 
have accelerated the identification of additional risk 
genes,3–5 including monoallelic ATP13A3 variants 
associated with adult- onset IPAH across genetic 
ancestries.3 4 6 7 ATP13A3 encodes a P- type ATPase, 
a cation transporter with a documented role in the 
polyamine transport system.8
Compared with adult- onset disease, childhood- 
onset PAH (cPAH) is marked by high morbidity, 
resistance to available therapies and poor survival.9 
Emerging data also indicate a strikingly different 
genomic architecture and distribution of genetic 
variants.4 9 10 De novo variants cause ~15% of 
cPAH. Monoallelic heritable variants in BMPR2, 
TBX4, ABCC8 and GDF2 likely cause 2%–6% of 
HPAH/IPAH in children, while variants in KCNK3, 
ACVRL1, ENG and SMAD9 are rare causes of 
cPAH.9 Biallelic variants in GDF2 and KCNK3 have 
been identified in very early- onset, severe cPAH 
in at least two families.11 12 Herein, we identified 
biallelic variants in ATP13A3 as the genetic cause of 
cPAH in three families including five affected chil-
dren presenting under 3 years of age.
PATIENT COHORT
Family 1
Proband II.1 presented with right heart failure at 
age 2.5 years. Echocardiography established right 
ventricular (RV) dilatation and hypertrophy with 
right atrial enlargement. Right heart catheteri-
sation (RHC) was deemed too risky and was not 
performed. The child was diagnosed with IPAH, 
treated with sildenafil and diuretics, but died at 4 
years of age due to right heart failure. The brother 
of the proband, II.2, was monitored from birth. At 
2.5 years of age, echocardiography revealed signs 
of suprasystemic pressure in the right ventricle 
with evidence of hypertrophy and dilation. There 
was also right- to- left shunting through a foramen 
ovale with percutaneous saturation of ~90%. RHC 
showed an elevated mean pulmonary artery pres-
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(dual oral bosentan and sildenafil supplemented with epopro-
stenol after 15 months), the patient required lung transplanta-
tion at age 4.5 years. He died at age 8.5 years after contracting 
pneumonia. Both parents (I.1 and I.2) and a sister (II.3) remain 
healthy with no signs of PAH. The family is of Slovenian descent 
(table 1).
Family 2
Proband II.2 was born at 30 weeks’ gestation, weighing 790 g. 
After 2 months in the neonatal intensive care unit, he was 
discharged home. At age 6 months, he was taken to his primary 
care provider due to delayed developmental milestones and 
episodes of cyanosis. Echocardiography demonstrated severe 
PAH with RV pressure greater than 71 mm Hg. There was no 
congenital heart disease. RHC showed a mPAP of 34 mm Hg 
with a pulmonary vascular resistance (PVR) index of 11.8 
Woods units that did not respond to oxygen or inhaled nitric 
oxide (iNO). Following a cardiac arrest during recovery from 
the procedure, he was supported by extracorporeal membrane 
oxygenation for 10 days. Despite extubation and maintenance 
therapy, he remained in critical condition and died of sepsis and 
PAH at age 11 months.
The proband’s sibling, II.4, was born at 37 weeks’ gestation. 
Echocardiography on the first day of life showed an estimated 
near systemic RV systolic pressure. At age 1 week, she developed 
persistent cyanotic episodes, with oxygen saturations in the 70 s 
and respiratory distress. RV pressure was observed to be supra-
systemic by echocardiography. She was initially treated with 
inhaled epoprostenol and NO, vasopressors and mechanical 
ventilation. She then received extracorporeal membrane oxygen-
ation for 5 days, due to acute decompensation. She subsequently 
responded to oxygen, diuretics, sildenafil, bosentan and trepros-
tinil and was discharged at age 2 months. Follow- up echocardi-
ography showed near systemic RV pressure and moderate RV 
hypertrophy. RHC at age 9 months showed a mPAP of 51 mm 
Hg with a PVR index of 11.8 Woods units, and these did not 
improve substantively with iNO and oxygen. Vasoreactivity 
testing showed no response until inhaled epoprostenol was 
added to 100% oxygen and iNO, perhaps indicating more refrac-
tory disease requiring engagement of both cyclic AMP and GMP 
pathways to maximise vasodilatation. She died at age 17 months, 
after contracting a respiratory infection. Both parents (I.1 and 
I.2) and two siblings (II.1 and II.3) remain healthy with no signs 
of PAH. The family is of Ashkenazi Jewish ancestry (table 1).
Family 3
Proband II.3 presented with severe PAH and right heart failure 
at age 22 months. Echocardiography and chest CT angiogram 
established RV dilatation and hypertrophy with right atrial 
enlargement. RHC demonstrated suprasystemic pulmonary 
artery pressure, a PVR of 34.3 and a low cardiac index (CI 1.7) 
that was mildly responsive to oxygen and iNO (PVR decreased 
to 25.5). Given her severe presentation and pulmonary haemo-
dynamics, balloon dilatation of her patent foramen ovale was 
performed. Triple therapy (subcutaneous remodulin, oral 
bosentan and oral sildenafil) was initiated for 1 year, but haemo-
dynamic values were only modestly improved (PVR 12.5, CI 
3.6), with a mild response to oxygen and iNO (PVR decreased 
to 9.8). Despite continued triple therapy, she re- presented with 
signs of right heart failure 6 months later. RHC showed supra-
systemic pulmonary artery pressure and a PVR of 22 that was 
unresponsive to oxygen and iNO. An MRI demonstrated a RV 
ejection fraction of 49%. Given her malignant course that was 
refractory to therapy, a Potts shunt was performed via left thora-
cotomy. Three months after her Potts procedure, she has much 
improved exercise tolerance. Both parents (I.1 and I.2) and two 
siblings (II.1 and II.2) are asymptomatic, and her sibling II.2 




Family 1 was recruited for genetic analysis through the NIHR 
BioResource for Rare Diseases programme.13 Family 2 was 
enrolled into a genetic study of PAH reviewed by the Columbia 
University Irving Medical Center institutional review board. 
Family 3 was enrolled in a research protocol approved by the 
University of California San Francisco institutional review board. 
All family members who were genetically assessed provided 
informed consent for themselves or their children.
Molecular genetic analysis
For family 1, DNA was extracted from whole blood samples for 
I.1, I.2 and II.2 and from a dried blood spot from the proband 
II.1 using the truXTRAC DBS Kit (Covaris). Parent–offspring 
trio (I.1, I.2 and II.2) whole genome sequencing was performed 
as described.3 For family 2, chromosomal microarray analysis 
and clinical exome sequencing were performed using blood- 
derived DNA from II.2 and II.4. Reanalysis of exome sequencing 
data screened 19 PAH risk genes1 14 (ACVRL1, AQP1, ATP13A3, 
BMPR1B, BMPR2, CAV1, CD248, EFCABB4B, EIF2AK4, ENG, 
GDF2, KCNA5, KCNK3, KLF2, SMAD1, SMAD4, SMAD9, 
SOX17 and TBX4). Analysis of Family 3 proband II.1 employed 
targeted sequencing of 21 genes associated with PAH (ABCC8, 
ACVRL1, AQP1, ATP13A3, BMPR1B, BMPR2, CAV1, EIF2AK4, 
ENG, FOXF1, GDF2, KCNA5, KCNK3, KLF2, NFU1, NOTCH3, 
RASA1, SMAD4, SMAD9, SOX17 and TBX4).
Family 1 samples were sequenced using Illumina HiSeq (2500 
or X) technology, generating paired- end reads. All samples had 
a minimum read- depth coverage of 15× in ≥95% of targeted 
regions. Quality control, read mapping, variant calling and 
annotation were all conducted as described.3 Likely pathogenic 
variants were independently confirmed by Sanger sequencing. 
Families 2 and 3 underwent clinical sequencing by GeneDx15 
or Blueprint Genetics, respectively. Population allele frequen-
cies were obtained from the Genome Aggregation Database 
(gnomAD) V.2.1.1 (controls) database. In silico pathogenicity 
predictions were assessed using Combined Annotation Depen-
dent Depletion score, Sorting Intolerant from Tolerant and Poly-




Trio analysis identified a homozygous ATP13A3 missense variant 
(NM_001367549.1: c.2563G>A; p.Val855Met) in affected 
child II.2, which was heterozygous in both parents (I.1 and I.2) 
(table 1). The variant is absent from gnomAD and a non- PAH 
European cohort (n=6385)3 and is predicted to be deleterious 
using in silico analysis (table 1). The deceased sibling (II.1) was 
homozygous for p.Val855Met and the unaffected sister (II.3) 
homozygous for the reference allele (figure 1A). The grand-
parents of the affected brothers are from nearby villages poten-
tially indicating a common ancestor. The p.Val855Met variant 
resides in the likely kinase active cytoplasmic loop between the 
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a homozygous c.2563G>A substitution was recently reported 
in a Southern European cohort14 but variant cosegregation with 
affected relatives was not evaluated in this study.
Family 2
Targeted reanalysis detected compound heterozygous ATP13A3 
variants in both affected children (II.2 and II.4): c.2227C>T; 
p.Arg743Cys and c.2549dupT; p.Met850Ilefs*13. Both parents 
(I.1 and I.2) and two unaffected siblings (II.1 and II.3) are 
heterozygous for one of the two variants (figure 1A) but remain 
asymptomatic. The p.Arg743Cys missense variant is absent from 
gnomAD and is predicted to be deleterious in silico (table 1). 
The variant resides in the same cytoplasmic loop as the family 
1 variant (figure 1B), and a distinct monoallelic missense 
variant (c.2228G>T; p.Arg743Leu) impacting the same amino 
acid residue has been observed in an adult- onset IPAH case.4 
ATP13A3 is highly constrained for loss- of- function variants 
(pLoF=1).18 The p.Met850Ilefs*13 frameshift is extremely rare 
(allele frequency 9.21e-6, with no homozygotes observed in 
gnomAD) and has been reported in a monoallelic adult- onset 
IPAH case.4 Of note, the two allele counts reported in gnomAD 
are from the Ashkenazi Jewish population similar to our family.
Family 3
Targeted screening identified compound heterozygous variants 
of ATP13A3 in the affected child (II.1): c.3079dupT; p.Tr-
p1027Leufs*9 and c.3685G>T; p.Glu1229* (table 1). Both 
parents (I.1 and I.2) and one unaffected sibling (II.2) are hetero-
zygous for one of the two variants; another unaffected sibling 
(II.1) is homozygous for the reference allele (figure 1A). The 
c.3079dupT mutant transcript is likely degraded by nonsense- 
mediated decay (NMD). However, the nonsense variant, 
c.3685G>T, is located in the final exon of the gene and is there-
fore predicted to escape NMD19 leading to the production of an 
abnormal, potentially damaging protein product.
DISCUSSION
We report biallelic variants in ATP13A3 associated with very 
early age of PAH onset and high mortality in three independent 
families. The five variants are extremely rare or absent from 
gnomAD and predicted to be deleterious missense or loss- of- 
function variants. Some of the variants have been reported for 
monoallelic adult- onset PAH. Therefore, the relatively young 
parents and siblings of the affected children, who are currently 
asymptomatic heterozygous carriers, are at increased risk of 
developing PAH later in life. These data support a novel para-
digm of semi- dominant inheritance for ATP13A3 in cPAH.
ATP13A3 encodes a transmembrane cation transporter, 
which was recently shown to transport polyamines.8 Polyam-
ines are small metabolites required for normal cell growth and 
proliferation, and elevated concentrations have been reported 
in multiple cancers and, more recently, PAH.20 21 ATP13A3 is 
widely expressed in developing embryo and adult tissues,22 
including pulmonary arterial smooth muscle cells (PASMC).3 
Hypoxia, an environmental inducer of PAH, stimulates accumu-
lation of spermine leading to increased PASMC proliferation in 
model systems. We hypothesise that ATP13A3 variants predicted 
to alter transporter function disturb polyamine homeostasis. 
However, additional experiments are required to assess the 
disease mechanism.
Figure 1 Rare deleterious ATP13A3 variants in biallelic and monoallelic PAH. (A) Family pedigrees for cases with early- onset, severe biallelic PAH. Filled 
boxes and circles indicate affected individuals. ATP13A3 mutation status is detailed for each individual. (B) Sequence chromatograms illustrating identified 
ATP13A3 variants in families 1–3. (C) ATP13A3 topology model with locations of variants identified in all PAH cases, both novel (bold typeface) and 
previously reported (Graf 2018, Zhu 2019, Wang, 2019, Lerche 2019, Gelinas 2020). Missense variants are in black, predicted truncating/splice variants in 
red. The number of filled circles at a variant location indicates the number of unrelated PAH cases identified with the variant. Yellow, green and blue shaded 
areas represent the actuator, nucleotide- binding and phosphorylation domains, respectively. Amino acids are numbered according to the longest transcript 
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Identification of PAH causal genes and variants provides crit-
ical information to begin to tailor approaches for treatment and 
prognosis. In vitro analysis of patient- derived loss- of- function 
KCNK3 variants showed successful recovery of channel func-
tion in response to a phospholipase inhibitor, suggesting a novel 
therapeutic avenue for PAH.1 2 Similarly, experimental therapies 
targeting the polyamine transport system in cancer23 can now be 
tested in ATP13A3- targeted model systems relevant to PAH. An 
independent therapeutic approach includes adenoviral delivery 
of unmutated genes or molecular editing of mutated genes, in 
PAH relevant cell types, to restore normal gene expression or 
protein function, respectively. Finally, deep phenotyping and 
longitudinal follow- up of cases grouped by genetic diagnosis 
provides an opportunity to identify associated phenotypes to 
inform clinical care.
Emerging data from sequencing studies increases the utility of 
case- level genetic reanalysis. For family 2, the two affected chil-
dren underwent extensive genetic testing without a diagnosis, 
but sequencing reanalysis facilitated the identification of biallelic 
variants in the newly identified ATP13A3 gene. Our study indi-
cates that genetic reanalysis may be an appropriate strategy to 
prioritise genetic diagnoses when preterm infants do not follow 
the usual trajectory expected from the degree of prematurity or 
when clinical diagnoses are ambiguous.
Identification of biallelic ATP13A3 variants in three fami-
lies with severe cPAH, in conjunction with recently identified 
monoallelic variants in adult- onset PAH, indicates semidominant 
inheritance for the ATP13A3 gene. Biallelic inheritance indicates 
a dose- dependent threshold effect with implications for prog-
nosis and treatment strategies. Taken together, these findings 
demonstrate the growing importance of comprehensive genetic 
analyses in well- powered cPAH populations.
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